CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.CEL-SCI's lead investigational therapy, Multikine®* (Leukocyte Interleukin, Injection), is currently being developed as a potential therapeutic agent aimed at harnessing the patient's own immune system to produce an anti-tumor response. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark we have registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with our future anticipated regulatory submission for approval.

CEL-SCI Corporation

NexImmune is a biotechnology company focused on developing novel immunotherapies for the treatment of cancer and other diseases.

NexImmune

bluebird is a biotechnology company specializing in gene and cell therapy for severe genetic diseases and cancer.

bluebird

CytomX is a biotechnology company focused on developing Probody therapeutics for the treatment of cancer.

CytomX

Celldex is a biotechnology company specializing in the development of targeted therapeutics for the treatment of cancer and other difficult-to-treat diseases.

Celldex

Sensei Biotherapeutics Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases.

Sensei Biotherapeutics Inc

PDS Biotechnology is a biotechnology company specializing in the development of immunotherapies for the treatment of cancer and infectious diseases.

PDS Biotechnology

CEL-SCI Corporation is a clinical-stage biotechnology company focused on the research and development of immune system therapy for the treatment of cancer and other diseases.

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Feb 9, 2024 3:33 PM	58e8193f
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 9, 2024 3:33 PM	dfaf0794
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Feb 9, 2024 3:33 PM	b988ccf0
news basic	general	Feb 9, 2024 3:33 PM	de93b43f
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:CEL-SCI

CEL-SCI Corporation

Last Close

1.21

26/07 20:00

Market Cap

63.91M

Beta: -

Volume Today

58.27M

Avg: -